Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Singular Genomics Systems, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/09/2023 |
8-K
| Quarterly results|
Docs:
|
"### EX-99.1 Singular Genomics Systems, Inc. Statements of Operations Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Revenue $ 505 $ - $ 1,368 $ - Cost of revenue 597 - 1,404 - Gross margin - - Operating expenses: Research and development 12,624 12,061 24,854 22,707 Selling, general and administrative 14,887 12,182 28,091 23,556 Total operating expenses 27,511 24,243 52,945 46,263 Loss from operations Other income : Interest expense Interest and other income 2,295 428 4,299 584 Total other income 2,025 261 3,770 275 Net loss $ $ $ $ Net loss per share: Basic and diluted net loss per share $ $ $ $ Weighted-average shares used to compute basic and diluted net loss per share 72,510,020 70,779,326 72,218,280 70,893,059 EX-99.1 Singular Genomics Systems, Inc. Bala..." |
|
| 05/09/2023 |
8-K
| Quarterly results|
Docs:
|
"Singular Genomics Systems, Inc. Statements of Operations Three Months Ended March 31, 2023 2022 Revenue $ 863 $ - Cost of revenue 807 - Gross margin 56 - Operating expenses: Research and development 12,230 10,645 Selling, general and administrative 13,204 11,375 Total operating expenses 25,434 22,020 Loss from operations Other income : Interest expense Interest and other income 2,004 156 Total other income 1,745 14 Net loss $ $ Net loss per share: Basic and diluted net loss per share $ $ Weighted-average shares used to compute basic and diluted net loss per share 71,926,412 71,011,041 EX-99.1 Singular Genomics Systems, Inc. Balance Sheets March 31, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 129,283 $ 74,266 Short-term investments 96,790 170,310 Accounts rec..." |
|
| 03/02/2023 |
8-K
| Quarterly results|
Docs:
|
"Singular Genomics Systems, Inc. Statements of Operations Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Revenue $ 765 $ - $ 765 $ - Cost of revenue 789 - 789 - Gross margin - - Operating expenses: Research and development 10,760 9,455 46,199 32,655 Selling, general and administrative 11,746 10,218 47,264 28,624 Total operating expenses 22,506 19,673 93,463 61,279 Loss from operations Other income : Interest expense Change in fair value of convertible promissory notes" |
|
| 03/02/2022 |
8-K
| Quarterly results |
| 11/09/2021 |
8-K
| Quarterly results|
Docs:
|
"Singular Genomics Systems, Inc. Statements of Operations Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Operating expenses: Research and development $ 8,910 $ 6,080 $ 23,200 $ 15,431 Selling, general and administrative 8,551 1,698 18,406 4,518 Total operating expenses 17,461 7,778 41,606 19,949 Loss from operations Other income : Interest income 91 76 223 444 Interest expense Change in fair value of convertible promissory notes - - - Change in fair value of warrant liability - Other income 20 405 24 Net loss $ $ $ $ Net loss per share: Basic and diluted net loss per share $ $ $ $ Weighted-average shares used to compute basic and diluted net loss per share 71,721,861 10,726,496 38,553,685 10,507,732 Singular Genomics Systems, Inc. Condensed Balanc..." |
|
| 08/03/2021 |
8-K
| Quarterly results |
|
|